orilanolimab SC (ALXN1830 SC) / AstraZeneca - LARVOL DELTA

A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=12 | Terminated | Sponsor: Alexion Pharmaceuticals, Inc. | N=56 ➔ 12

Enrollment change

A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=56 | Terminated | Sponsor: Alexion Pharmaceuticals

New P1 trial

A Study of ALXN1830 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=48 | Terminated | Sponsor: Alexion Pharmaceuticals | Suspended ➔ Terminated; Sponsor decision to terminate program

Trial termination

WAIHA: Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Alexion Pharmaceuticals | N=36 ➔ 0 | Suspended ➔ Withdrawn

Enrollment change • Trial withdrawal • Anemia • Hematological Disorders • Immunology • HP

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis (clinicaltrials.gov) - P2a | N=0 | Withdrawn | Sponsor: Alexion Pharmaceuticals | N=24 ➔ 0 | Suspended ➔ Withdrawn

Enrollment change • Trial withdrawal • CNS Disorders • Myasthenia Gravis

WAIHA: Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia (clinicaltrials.gov) - P2; N=36; Suspended; Sponsor: Alexion Pharmaceuticals; Initiation date: Jul 2021 ➔ Jan 2022; Not yet recruiting ➔ Suspended

Clinical • Trial initiation date • Trial suspension • Anemia • Hematological Disorders • Immunology • HP

A Study of ALXN1830 in Healthy Adult Participants (clinicaltrials.gov) - P1; N=48; Suspended; Sponsor: Alexion Pharmaceuticals; Recruiting ➔ Suspended

Clinical • Trial suspension

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis (clinicaltrials.gov) - P2a; N=24; Suspended; Sponsor: Alexion Pharmaceuticals; Initiation date: Jul 2021 ➔ Jan 2022; Recruiting ➔ Suspended

Clinical • Trial initiation date • Trial suspension • CNS Disorders • Myasthenia Gravis

ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia ALXN1830 en pacientes con anemia hemolítica autoinmunitaria por anticuerpos calientes (clinicaltrialsregister.eu) - P2; N=36; Ongoing; Sponsor: Alexion Pharmaceuticals, Inc.

New P2 trial • Anemia • Hematological Disorders • Immunology • HP

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis (clinicaltrials.gov) - P2a; N=24; Recruiting; Sponsor: Alexion Pharmaceuticals

New P2a trial • CNS Disorders • Myasthenia Gravis

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia (clinicaltrials.gov) - P2; N=36; Not yet recruiting; Sponsor: Alexion Pharmaceuticals

Clinical • New P2 trial • Anemia • Complement-mediated Rare Disorders • Hematological Disorders • Immunology • HP

A Study of ALXN1830 in Healthy Adult Participants (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Alexion Pharmaceuticals; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study of ALXN1830 in Healthy Adult Participants (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Alexion Pharmaceuticals

Clinical • New P1 trial